INREBIC

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug INREBIC contains one active pharmaceutical ingredient (API):

1	Fedratinib UNII UH9J2HBQWJ - FEDRATINIB HYDROCHLORIDE
	Fedratinib is a kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). Fedratinib reduced JAK2-mediated phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited malignant cell proliferation in vitro and in vivo.
	Read more about Fedratinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INREBIC Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)
INREBIC Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EJ02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EJ Janus-associated kinase (JAK) inhibitors
Discover more medicines within L01EJ02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1840799
FR	Base de données publique des médicaments	65716809
GB	Medicines & Healthcare Products Regulatory Agency	396295
IL	מִשְׂרַד הַבְּרִיאוּת	8773
IT	Agenzia del Farmaco	049373018
LT	Valstybinė vaistų kontrolės tarnyba	1092140
PL	Rejestru Produktów Leczniczych	100448594
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68147001
US	FDA, National Drug Code	59572-720